Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview that will include an update on Enanta’s development pipeline, including preclinical data from Enanta’s new research program in non-alcoholic steatohepatitis (NASH), on January 14, 2015 at 11:00 a.m. PT during the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
